Source: Pharmacy Times articles
With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).
Read More
by MM360 Staff | May 8, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).
Read More